BRIEF published on 02/20/2025 at 07:35, 1 month 21 days ago Sensorion to Participate in March Investor Conferences Biotechnology Investor Conferences Sensorion Hearing Loss Therapies March 2025
PRESS RELEASE published on 02/20/2025 at 07:30, 1 month 21 days ago Inside Information / Other news releases Sensorion announces participation in investor conferences in March. CEO and CFO will attend Cowen and Leerink events to present company updates and meet investors Biotechnology CFO Investor Conferences CEO Sensorion
BRIEF published on 02/18/2025 at 07:35, 1 month 23 days ago Sensorion announces its participation in congresses in March 2025 Biotechnology Sensorion Hearing Therapies Medical Innovations Congress 2025
PRESS RELEASE published on 02/18/2025 at 07:30, 1 month 23 days ago Inside Information / Other news releases Sensorion announces participation in upcoming congresses in March to present on innovative biologics and manufacturing challenges for hearing loss disorders Sensorion Hearing Loss Biologics Congresses Manufacturing Challenges
BRIEF published on 02/12/2025 at 11:35, 2 months 1 day ago Sensorion to Participate in ARO 48th Annual Midwinter Meeting Sensorion Hearing Loss ARO Meeting GJB2-GT Therapy Biotech Conference
PRESS RELEASE published on 02/12/2025 at 11:30, 2 months 1 day ago Inside Information / Other news releases Sensorion announces participation in ARO 48th Annual Midwinter Meeting with focus on gene therapy for deafness. Details of presentations by Sensorion executives included Gene Therapy Sensorion ARO Meeting Deafness Sensorion Executives
BRIEF published on 12/27/2024 at 07:35, 3 months 17 days ago Sensorion Completes Enrollment for Audiogene Phase 1/2 Trial Gene Therapy Sensorion Hearing Loss SENS-501 Audiogene Trial
PRESS RELEASE published on 12/27/2024 at 07:30, 3 months 17 days ago Inside Information / Other news releases Sensorion completes enrollment of the first cohort in the Audiogene Phase 1/2 gene therapy clinical trial, targeting infants with hearing loss disorders Gene Therapy Clinical Trial Sensorion Hearing Loss Disorders Audiogene
BRIEF published on 12/18/2024 at 07:35, 3 months 26 days ago Sensorion Reports Positive Preliminary Results for SENS-501 Gene Therapy Clinical Trial SENS-501 Congenital Deafness Biotechnological Innovation
PRESS RELEASE published on 12/18/2024 at 07:30, 3 months 26 days ago Inside Information / Other news releases Sensorion reports positive safety data and behavioral changes in toddlers from the Audiogene Phase 1/2 Gene Therapy Clinical Trial. Plans KOL event in 2025 for further discussion Gene Therapy Clinical Trial Sensorion Hearing Loss Audiogene
Published on 04/12/2025 at 15:45, 1 day 14 hours ago New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presid
Published on 04/12/2025 at 02:00, 2 days 3 hours ago Battery X Metals Announces Provisional Patent Application with United States Patent & Trademark Office for Lithium-Ion Battery Rebalancing Technology Innovations
Published on 04/12/2025 at 00:10, 2 days 5 hours ago Applied Minerals, Inc. Files Motion to Approve Disclosure Statement
Published on 04/11/2025 at 23:45, 2 days 6 hours ago Gold Terra Closes First Tranche of Financing Package with Support from Osisko Gold Royalties
Published on 04/11/2025 at 21:45, 2 days 8 hours ago OPPO Unveils Agentic AI Initiative at Google Cloud Next 2025, Showcasing Innovations and Leadership in AI Experiences
Published on 04/11/2025 at 18:38, 2 days 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/11/2025 at 18:23, 2 days 11 hours ago EQS-Adhoc: Cherry SE: Cherry SE recognizes asset impairment for 2024; updates adjusted EBITDA margin for fiscal year 2024
Published on 04/11/2025 at 18:30, 2 days 11 hours ago Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:00, 2 days 11 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Published on 04/11/2025 at 17:45, 2 days 12 hours ago NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
Published on 04/11/2025 at 13:49, 2 days 16 hours ago Statement about the number of shares composing the share capital and the number of voting rights as at March 31, 2025
Published on 04/11/2025 at 13:36, 2 days 16 hours ago Number of shares and voting rights - March 2025 (In French only)
